Sun Pharmaceutical Industries Ltd (SUNPHARMA) Q1 FY27 Results Analysis: PAT Jumps 27%, EBITDA Margin Compresses 220 bps

Sun Pharmaceutical Industries Ltd's Q1 FY27 numbers came in strong, with revenue of Rs. 15,300.00 Cr (+10.50% YoY) and PAT growth of +27.00% YoY. Here's a quick read of what worked, what to watch, and what management said.

Quarter Snapshot

Q1 revenue growth of 10.5% YoY exceeded management's high single-digit guidance, driven by strong India performance (+16%) and Innovative Medicines (+12.8% USD). PAT grew 27% YoY, though EBITDA margin contracted 220bps due to cost pressures. US generics remained weak (-9.7% USD). The Organon acquisition is on track for early 2027 closing, providing a long-term catalyst. Overall, a solid quarter with a revenue beat but margin compression warrants caution.

Key Investment Insights

Key Positives

• Revenue grew 10.5% YoY to Rs.152,999 Mn, exceeding management's high single-digit guidance
• PAT grew 27.0% YoY to Rs.28,948 Mn, aided by lower exceptional items
• India formulations grew 16.0% YoY, gaining market share to 8.5% (up 30 bps)
• Innovative Medicines segment grew 12.8% YoY in USD, now 21.9% of sales
• Normalized PAT (ex-exceptionals) grew 3.1% YoY to Rs.30,894 Mn
• Organon acquisition on track with stockholder approval received and closing expected early 2027

Risk Factors

• US formulations declined 9.7% YoY in USD due to pricing pressure and compliance issues
• EBITDA margin contracted 220 bps YoY to 28.9%, driven by higher employee costs and acquisition expenses
• Employee benefits expense grew 15.2% YoY, outpacing revenue growth
• Finance costs increased 33.3% YoY, reflecting higher interest burden
• Effective tax rate of 29.0% exceeded the expected 25.168% due to non-deductible exceptional items
• R&D spend at 5.4% of sales was below the 6-7% guidance range